Novo Nordisk A/S (NYSE:NVO) Shares Sold by Wealthspire Advisors LLC

Wealthspire Advisors LLC lowered its position in shares of Novo Nordisk A/S (NYSE:NVO) by 19.0% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 12,875 shares of the company’s stock after selling 3,013 shares during the quarter. Wealthspire Advisors LLC’s holdings in Novo Nordisk A/S were worth $1,107,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Tradewinds Capital Management LLC boosted its position in shares of Novo Nordisk A/S by 2.6% during the 4th quarter. Tradewinds Capital Management LLC now owns 4,984 shares of the company’s stock valued at $429,000 after purchasing an additional 124 shares in the last quarter. Cohen Capital Management Inc. acquired a new stake in Novo Nordisk A/S during the fourth quarter valued at approximately $227,000. Indie Asset Partners LLC boosted its holdings in Novo Nordisk A/S by 4.2% during the fourth quarter. Indie Asset Partners LLC now owns 3,128 shares of the company’s stock worth $269,000 after buying an additional 126 shares in the last quarter. Dividend Assets Capital LLC grew its position in Novo Nordisk A/S by 3.1% in the fourth quarter. Dividend Assets Capital LLC now owns 214,615 shares of the company’s stock worth $18,461,000 after buying an additional 6,395 shares during the last quarter. Finally, Outfitter Financial LLC increased its holdings in shares of Novo Nordisk A/S by 9.9% in the fourth quarter. Outfitter Financial LLC now owns 8,795 shares of the company’s stock valued at $757,000 after buying an additional 795 shares in the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Trading Up 2.8 %

Shares of NYSE NVO opened at $90.58 on Tuesday. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. Novo Nordisk A/S has a one year low of $77.82 and a one year high of $148.15. The business has a 50-day moving average price of $85.66 and a two-hundred day moving average price of $107.72. The firm has a market capitalization of $406.48 billion, a PE ratio of 27.53, a PEG ratio of 0.90 and a beta of 0.45.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be issued a dividend of $0.7874 per share. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a dividend yield of 1.2%. The ex-dividend date of this dividend is Monday, March 31st. Novo Nordisk A/S’s payout ratio is currently 21.88%.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on NVO. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. BMO Capital Markets reduced their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. Finally, StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Novo Nordisk A/S presently has an average rating of “Moderate Buy” and an average price target of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.